Eledon Pharmaceuticals (ELDN) Preferred Stock Liabilities (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 7 years of Preferred Stock Liabilities data on file, last reported at $53.5 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $53.5 million; the trailing twelve-month figure through Mar 2026 stood at $53.5 million (changed 0.0% YoY), and the FY2025 full-year result was $53.5 million, up 2389.21% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $53.5 million, roughly flat from $53.5 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $53.5 million in Q1 2025 and bottomed at $2.2 million in Q4 2023.
• The 5-year median for Preferred Stock Liabilities is $2.2 million (2023), against an average of $20.9 million.
• The widest annual swing landed in 2023, when Preferred Stock Liabilities slipped 28.7%; it then surged 2389.21% in 2025.
• A 5-year view of Preferred Stock Liabilities shows it stood at $3.0 million in 2022, then retreated by 28.7% to $2.2 million in 2023, then changed by 0.0% to $2.2 million in 2024, then soared by 2389.21% to $53.5 million in 2025, then changed by 0.0% to $53.5 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $53.5 million (Q1 2026), $53.5 million (Q4 2025), and $53.5 million (Q3 2025), per Business Quant data.

Peer Comparison